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Abstract
 
The human tyrosinase-derived peptide 
 
Y
 
MDGTMSQV is presented on the surface of human
 
histocompatibility leukocyte antigen (HLA)-A
 
*
 
0201
 
1
 
 melanomas and has been suggested to be
a tumor antigen despite the fact that tyrosinase is also expressed in melanocytes. To gain infor-
mation about immunoreactivity and self-tolerance to this antigen, we established a model using
the murine tyrosinase-derived homologue of this peptide 
 
F
 
MDGTMSQV, together with
transgenic mice expressing the HLA-A
 
*
 
0201 recombinant molecule AAD. The murine pep-
tide was processed and presented by AAD similarly to its human counterpart. After immuniza-
tion with recombinant vaccinia virus encoding murine tyrosinase, we detected a robust AAD-
restricted cytotoxic T lymphocyte (CTL) response to 
 
F
 
MDGTMSQV in AAD transgenic mice
in which the entire tyrosinase gene had been deleted by a radiation-induced mutation. A resid-
ual response was observed in the AAD
 
1
 
tyrosinase
 
1
 
 mice after activation under certain condi-
tions. At least some of these residual CTLs in AAD
 
1
 
tyrosinase
 
1
 
 mice were of high avidity and
induced vitiligo upon adoptive transfer into AAD
 
1
 
tyrosinase
 
1
 
 hosts. Collectively, these data
suggest that 
 
F
 
MDGTMSQV is naturally processed and presented in vivo, and that this presen-
tation leads to substantial but incomplete self-tolerance. The relevance of this model to an un-
derstanding of the human immune response to tyrosinase is discussed.
Key words: tyrosinase • self-tolerance • MHC class I • cytotoxic T lymphocytes • 
immunotherapy
 
Introduction
 
CTLs derived from patients with melanoma have been
shown to recognize Ags expressed on allogeneic melanoma
in addition to autologous tumor (1–8). Characterization of
these “shared” melanoma Ags has established that they are
peptides restricted by class I MHC molecules and are de-
rived from a variety of source proteins. These include de-
velopmentally regulated proteins that are silent in most
normal tissues, with the exception of their expression in
spermatogonia and primary spermatocytes of the testis, but
become activated in several types of tumor cells (MAGE [9,
10], BAGE [11], and GAGE [12]). Shared melanoma anti-
gens also include melanocyte differentiation proteins
 
(MDPs)
 
1
 
 that are normally expressed only in cells of the
melanocytic lineage (tyrosinase [13–15], pMEL17/gp100
[2, 3, 16], gp75/tyrosinase-related protein [TRP]-1 [17],
MART-1/Melan-A [4], and TRP-2 [18]). CTLs specific
for MDP-derived Ags have been found in the metastatic
LNs of melanoma patients (19, 20), but the presence of
these CTLs sometimes correlates with the loss of MDP ex-
pression (21). Although MDPs are commonly expressed in
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Abbreviations used in this paper:
 
 IC
 
50
 
, half-maximal inhibitory concentra-
tion; M1, matrix protein 1; MDP, melanocyte differentiation protein;
rvv-hu tyr, full-length human tyrosinase recombinant vaccinia virus; rvv-
M1, full-length matrix protein 1 from influenza A/PR/8; rvv-mu tyr,
full-length murine tyrosinase recombinant vaccinia virus; TRP, tyrosi-
nase-related protein. 
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primary tumors, they are absent in 
 
z
 
30% of metastatic
melanomas (22, 23). Nevertheless, immunotherapies that
target MDP
 
1
 
 tumors and utilize MDP-derived Ags induce
positive clinical responses (24, 25). Taken together, these
results suggest that an immune response against MDP-derived
Ags may be an important aspect of the patient’s ability to
control tumor outgrowth.
Several ongoing clinical trials for melanoma immuno-
therapy are focused on targeting the immune response to
MDP-derived Ags (24, 25). Since spontaneous regression
of melanomas as well as clinical responses after IL-2 therapy
correlate with the destruction of normal melanocytes (viti-
ligo) (26, 27), it is important to understand which of the
MDP-derived Ags are associated with the development of
vitiligo (28). Insight is provided by studies demonstrating
that CTLs specific for some MDP-derived peptide Ags rec-
ognize human melanocyte cell lines cultured in the pres-
ence of growth factors (29–32; and our unpublished re-
sults), suggesting that these Ags may be targets of the
immune response that mediates vitiligo. However, the in-
fluence of such growth factors on the profile of Ags pre-
sented is not clear. In addition, MHC tetramers have been
used to show an accumulation of MDP-specific CTLs in
lesions of vitiligo patients (33). Although these studies have
provided some information about the Ags that may lead to
the development of vitiligo, they have not examined the
influence of normal melanocyte expression and/or presen-
tation of MDP-derived Ags on an antitumor immune re-
sponse.
To address these issues, we wished to evaluate whether
MDP-derived Ags are presented by normal melanocytes in
vivo and to determine how self-tolerance and autoreactiv-
ity to these Ags influences the immune response. We have
taken advantage of a recently described albino strain in
which the entire coding sequence for tyrosinase has been
deleted (34). This deletion precludes processing and pre-
sentation of Ags derived from tyrosinase. Because no ty-
rosinase-derived epitopes have been described that are pre-
sented by murine class I MHC molecules, we have also
used transgenic mice that express a chimeric human MHC
class I transgene encoding the 
 
a
 
1 and 
 
a
 
2 domains from
HLA-A
 
*
 
0201 and the 
 
a
 
3, transmembrane, and cytoplasmic
domains from D
 
d
 
 (AAD) (35). We have previously identi-
fied a peptide (
 
Y
 
MDGTMSQV) that is derived from the
MDP tyrosinase, presented by HLA-A
 
*
 
0201
 
1
 
 human mel-
anomas, and recognized by patient CTLs (15). In this
study, we have examined whether 
 
F
 
MDGTMSQV, the
murine homologue of 
 
Y
 
MDGTMSQV, is presented in
vivo by murine melanocytes and have evaluated the im-
pact of tyrosinase expression on the development of a
 
F
 
MDGTMSQV-specific CTL immune response.
 
Materials and Methods
 
Cell Lines and Transfectants.
 
EL4-A2/K
 
b
 
 (gift of Dr. Linda
Sherman, The Scripps Research Institute, La Jolla, CA) is a trans-
fectant of the murine thymoma EL4 (H-2
 
b
 
 haplotype) that ex-
presses A2/K
 
b
 
. The transfectant of the B lymphoblastoid cell line
 
C1R expressing AAD has been described previously (36). AAD is
a hybrid MHC class I molecule that contains the 
 
a
 
1 and 
 
a
 
2 do-
mains from HLA-A
 
*
 
0201 and the 
 
a
 
3 domain of the H-2D
 
d
 
 mol-
ecule, and has been described previously (37).
 
Peptides.
 
Synthetic peptides were made by standard Fmoc
chemistry using a peptide synthesizer (model AMS422; Gilson
Company, Inc.). All peptides were purified to 
 
.
 
98% purity by
reverse-phase HPLC on a C-8 column (Vydac). Purity and iden-
tity were established using an LCQ Finnigan Mat mass spectrom-
eter with electrospray ionization.
 
Recombinant Vaccinia Viruses.
 
Viruses encoding full-length
human tyrosinase (rvv-hu tyr) have been described previously
(38). The full-length murine tyrosinase recombinant vaccinia vi-
rus (rvv-mu tyr) has also been described (39). Virus encoding the
full-length matrix protein 1 (M1) from influenza A/PR/8 (rvv-
M1) was a gift from Jack Bennink (National Institutes of Health).
Purified vaccinia virus stocks were titered and tested for proper
expression using specific murine HLA-A
 
*
 
0201–restricted CTLs.
 
Class I Peptide Binding Affinity Assays.
 
The relative affinities
of peptides for HLA-A
 
*
 
0201 molecules were measured as de-
scribed (40). In brief, affinity-purified HLA-A
 
*
 
0201 molecules
were incubated at room temperature with an iodinated indicator
peptide (FLPSDYFPSV) and graded doses of test peptides in PBS,
pH 7.0, containing 0.05% NP-40, 1 
 
m
 
M human 
 
b
 
2-microglobu-
lin (Calbiochem), 1 mM PMSF, 1.3 mM 1,10-phenanthroline,
73 
 
m
 
M pepstatin A, 8 mM EDTA, and 200 
 
m
 
M 
 
N
 
a
 
-
 
p
 
-tosyl-
 
l
 
-
lysine chloromethyl ketone (TLCK). After 48 h, class I peptide
complexes were separated from free peptides by gel filtration, and
the dose of individual test peptides that reduced the binding of
indicator peptide by 50% (IC
 
50
 
) was calculated.
 
Mice.
 
C57BL/6 mice transgenic for the AAD gene have
been described previously (41). Mice carrying the 38R145L neu-
tron radiation–induced deletion at the tyrosinase (
 
c
 
) locus on
mouse chromosome 7 (
 
c
 
38R145L
 
/
 
c
 
38R145L
 
) have been described pre-
viously (34). Transmission of this deletion in heterozygous form
was determined by PCR analysis using MapPair primers that de-
fine 
 
D7Mit62
 
 and 
 
D7Mit301
 
 (Research Genetics). These markers
lie 
 
,
 
2 cM from either side of the tyrosinase gene (42).
 
Generation of CTL Lines.
 
8-wk-old mice were immunized
intraperitoneally with 10
 
7
 
 PFU of recombinant vaccinia virus ex-
pressing murine tyrosinase, human tyrosinase, or influenza M1.
After 3 wk, 7.5 
 
3
 
 10
 
6
 
 splenocytes from primed mice were cocul-
tured in 24-well plates with 3.5 
 
3
 
 10
 
6
 
 irradiated (2,000 rads) au-
tologous splenocytes that had been pulsed with various concen-
trations of the indicated synthetic peptide antigens. After 6 d of
coculture, activity was measured by standard 
 
51
 
Cr-release assay.
CTL lines were established from these primary cultures in 12-
well plates (Corning Costar) by weekly culture of 5 
 
3
 
 10
 
5
 
 CTLs/
well with 5 
 
3
 
 10
 
6
 
 irradiated (2,000 rads) C57BL/6 AAD
 
1
 
 pep-
tide-pulsed and washed spleen cells. CTL lines specific for
 
F
 
MDGTMSQV are referred to as FMD 10, FMD 1, FMD 0.1,
or FMD 0.01 to indicate the concentration of peptide (in 
 
m
 
g/ml)
used to pulse the stimulators. Murine CTL lines specific for the
HLA-A2–restricted peptides 
 
Y
 
MDGTMSQV (human tyros-
inase
 
369–377
 
) or GILGFVFTL (influenza M1
 
58–66
 
) (43) are referred
to as CJL and M1, respectively. All murine CTL lines were grown
in RPMI 1640 supplemented with 2 mM 
 
L
 
-glutamine, sodium
pyruvate, essential and nonessential amino acids, penicillin/strep-
tomycin, 50 
 
m
 
M 
 
b
 
-mercaptoethanol, 10% FBS, 15 mM Hepes,
and 10 U/ml of IL-2 in a humidified 8% CO
 
2
 
 atmosphere at
37
 
8
 
C.
 
In Vitro Cytotoxicity Assay.
 
Standard 
 
51
 
Cr-release assays were
performed to determine CTL recognition of murine and human 
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tyrosinase
 
369–377
 
 peptides. For peptide dose–response assays, 
 
51
 
Cr-
labeled EL4-A2/K
 
b
 
 cells were incubated with the indicated con-
centrations of synthetic peptides for 3 h at room temperature.
Con A blasts were generated by incubating 5 
 
3 
 
10
 
6
 
 spleen cells/
ml in 10 ml of RPMI medium containing 2 
 
m
 
g/ml of Con A for
72 h in a 25-cm
 
2
 
 upright tissue culture flask in a humidified 5%
CO
 
2
 
 atmosphere at 37
 
8
 
C. For vaccinia-infected target cells, 10
PFU/cell were added to 10
 
6
 
 target cells in 1 ml HBSS supple-
mented with 0.1% BSA, 1.6 mM MgSO
 
4
 
, and 1.8 mM CaCl
 
2
 
 for
1 h and then 4 ml of RPMI 1640 supplemented with 10% FBS
was added for 8 h.
 
Enrichment of CD8
 
1
 
 
 
T Cells.
 
CD8
 
1 
 
T cells from spleens of
immunized mice were isolated from a StemSep column after in-
cubation with a cocktail of antibodies to enrich for CD8
 
1 
 
cells
(StemCell). Preparations were consistently 85–95% CD81 as as-
sessed by flow cytometry conducted on a FACScan™ using
CELLQuest™ software (Becton Dickinson).
Analysis of Intracellular IFN-g Production. Peptide-pulsed stim-
ulator cells were incubated with CD81 T cells for 5 h at a ratio of
1:1 in media supplemented with 50 U/ml IL-2 and 10 mg/ml
brefeldin A (Sigma Chemical Co.). Stimulated cells were stained
with PE-conjugated anti-CD8 (PharMingen), washed, fixed and
permeabilized in Cytofix/Cytoperm (PharMingen), further
stained with FITC-conjugated anti–IFN-g (PharMingen) or iso-
type-matched controls, and analyzed by flow cytometry. Results
are presented as percent positive cells after subtraction of isotype
control values.
Adoptive Cell Transfer. 2 d after the last in vitro stimulation,
107 CJL, FMD 1, or M1 CTLs were subcutaneously transferred
into irradiated (700 rads) AAD1 or AAD2 C57BL/6 mice with
or without 5,000 Cetus U of Proleukin (IL-2; Chiron). Mice that
received the initial dose of IL-2 received additional IL-2 (5,000
Cetus U) intraperitoneally each day for 4 d after CTL transfer.
Mice were examined each week for 4 wk for evidence of coat
color changes.
Results
Murine Tyrosinase369–377 Is Homologous to Human Tyros-
inase369–377 and Binds to HLA-A*0201. The amino acid
sequences of murine and human tyrosinase proteins are
82% homologous, and almost identical in the region sur-
rounding residues 369–377,2 from which the HLA-A*0201–
restricted melanoma Ag YMDGTMSQV is derived. With
the exception of position 369 of this sequence, in which Y
is substituted by an F residue, the 11 amino acids upstream
and 30 amino acids downstream of the human epitope are
identical to those in the murine protein (Fig. 1). As the
human epitope undergoes a posttranslational modification
in which N371 is converted to a D (15, 38), it seemed
likely that the homologous murine peptide would also un-
dergo this modification and would be presented by HLA-
A*0201 similarly to the human tyrosinase Ag. When the
relative affinity of the murine tyrosinase369–377 peptide con-
taining a D at position 371 (FMDGTMSQV) for purified
HLA-A*0201 was measured in a competitive binding assay
(15), the concentration that inhibited the binding of the
iodinated standard peptide to purified HLA-A*0201 by
50% (IC50) was nearly identical to the IC50 value of the
human tyrosinase369–377 peptide (YMDGTMSQV) (Table
I). Thus, this murine homologue of the human tyrosinase-
derived melanoma Ag could potentially be presented by
HLA-A*02011 cells and recognized by CTLs.
HLA-A*0201–restricted CTLs Specific for Human Tyros-
inase369–377 Cross-react on the Homologous Murine Peptide.
To provide direct evidence for the immunological recogni-
tion of FMDGTMSQV, we used CTLs that had been elic-
ited against YMDGTMSQV (38). We found that several
such CTL lines recognized EL4-A2/Kb target cells that
had been pulsed with similar concentrations of either the
human or murine peptides (Fig. 2 A, and data not shown).
Similarly, we elicited CTLs from AAD1 mice against
FMDGTMSQV (FMD 1) and found that they had a simi-
lar affinity for both peptides, as determined from the con-
centration required to give half-maximal lysis (Fig. 2 B).
Collectively, these results confirm that the murine and hu-
man tyrosinase-derived peptides bind to HLA-A*0201 and
are sufficiently homologous to be recognized by the same
CTLs.
Murine Tyrosinase369–377 Is Naturally Processed and Pre-
sented. The preceding results demonstrated that a syn-
thetic peptide corresponding to the sequence derived from
murine tyrosinase369–377 could be presented by HLA-
A*0201 when added to cells. To determine whether this
peptide could be naturally processed and presented, we in-
fected cells with rvv-mu tyr. For this purpose we used C1R-
AAD, a tyrosinase2 B lymphoblastoid cell line that had
been transfected with AAD. When infected with either
the rvv-mu tyr or rvv-hu tyr, these cells were lysed by
FMD 1 CTLs, which recognize murine tyrosinase369–377
(Fig. 2 C). These results confirmed that murine
2The sequence YMNGTMSQV from the tyrosinase gene was initially
identified as residues 368–376 (13), and this laboratory had previously
used that numbering system (38). The correct numbering for the YM-
NGTMSQV peptide is 369–377.
Figure 1. Sequence homology of murine and human
tyrosinase in the region surrounding residues 369–377.
Table I. Binding Affinities of Human and Murine
Tyrosine-derived Peptides for HLA-A*0201
Origin Sequence IC50
nM
Human YMDGTMSQV 74
Murine FMDGTMSQV 65
IC50 values were determined by measuring the binding of the indicated
synthetic peptides to purified HLA-A*0201, as described in Materials
and Methods.1224 Tolerance to Murine Homologue of Tyrosinase-derived Melanoma Antigen
tyrosinase369–377 can be naturally processed and presented
in association with HLA-A*0201 molecules.
T Cell Responses to Murine Tyrosinase369–377 in Tyrosinase1
and Tyrosinase2 Mice. To test the impact of tyrosinase ex-
pression on CTL response to murine tyrosinase369–377, we
compared AAD1 mice (which are of C57BL/6 origin and
tyrosinase1) with 38R145L mice, from which the tyrosinase
coding sequence at the c locus has been deleted (34). The lat-
ter were crossed to AAD1 mice, and progeny positive for
both markers were intercrossed to produce AAD1 mice that
were c1/c1, c1/c38R145L, or c38R145L/c38R145L. While the first
two genotypes were normally pigmented, animals with the
third genotype were albino. After immunization of each type
of animal with rvv-mu tyr, spleen cells were cultured with
autologous splenocytes pulsed with FMDGTMSQV, and
the CTL response was measured 6 d later. CTLs from im-
munized AAD1c38R145L/c38R145L mice (hereafter referred to as
AAD1 albino) recognized FMDGTMSQV peptide–pulsed
EL4-A2/Kb targets (Fig. 3 A). In contrast, T cells from im-
munized AAD1 mice that were either c1/c38R145L or c1/c1
(hereafter referred to as AAD1tyrosinase1) exhibited no sig-
nificant response to targets presenting FMDGTMSQV (Fig.
3, B and C). These results indicate that expression of tyrosi-
nase is associated with a dramatic reduction in the response
to this tyrosinase-derived peptide.
Several additional experiments were done to confirm
that the CTL response observed in AAD1 albino mice was
dependent on the AAD molecule. First, albino mice that
did not express AAD also failed to mount a specific CTL
response after immunization with rvv-mu tyr and in vitro
restimulation with FMDGTMSQV peptide (Fig. 3 D).
Second, although FMDGTMSQV-specific CTLs from
AAD1 albino mice recognized peptide-pulsed EL4-A2/Kb
transfectants, they failed to recognize peptide-pulsed but
untransfected EL4 cells (Fig. 3 A). Similarly, these CTLs
recognized peptide-pulsed Con A blasts from AAD1, but
not AAD2 littermates (Fig. 4). These results establish that
the CTL response in rvv-mu tyr–immunized AAD1 albino
mice is AAD restricted and confirms that FMDGTMSQV
cannot be presented by murine restriction elements ex-
pressed in the outbred albino strain.
We also examined the impact of tyrosinase expression on
the T cell response to FMDGTMSQV by the quantitation
of IFN-g production by CD81 cells from spleens of rvv-
mu tyr–immunized mice. As observed for cytotoxic activ-
ity, a significant number of CD81 cells from AAD1 albino
mice produced IFN-g at the peak of the response to rvv-
mu tyr, whereas no IFN-g production was discernible in
CD81 cells from AAD1tyrosinase1 mice (Fig. 5). Based on
the observation that the AAD-restricted murine and hu-
man tyrosinase epitopes were recognized in a cross-reactive
manner by CTLs, we also examined responses in AAD1 al-
bino mice and AAD1tyrosinase1 mice after immunization
with rvv-hu tyr. A strong response was observed in AAD1
albino mice that was largely cross-reactive on the murine
tyrosinase-derived peptide. In contrast, a much weaker re-
sponse after immunization with rvv-hu tyr was observed in
AAD1tyrosinase1 mice, and no significant cross-reactivity
on the murine tyrosinase epitope was detectable. Taken to-
gether, we conclude that in vivo presentation of FMDGT-
MSQV by the AAD molecule in AAD1tyrosinase1 mice
results in a substantially diminished CTL response to both
the murine tyrosinase-derived peptide and its human ho-
mologue.
A Residual Tyrosinase-specific Response Exists in Tyrosinase1
Mice. The preceding results demonstrated that there was
no detectable FMDGTMSQV-specific CTL response from
immunized AAD1tyrosinase1 mice either at the peak of the
primary response or after secondary in vitro stimulation.
These results appeared at odds with our previous demon-
stration that CTL lines elicited against the human tyrosi-
nase epitope recognize the murine tyrosinase-derived pep-
Figure 2. Murine tyrosinase369–377 is naturally processed and presented
in vivo. (A) 51Cr-labeled EL4-AAK cells that had been pulsed with the
indicated concentration of either murine (r) or human (j) tyrosinase
peptides were incubated with CJL CTLs stimulated by and reactive with
human tyrosinase369–377 at an E/T ratio of 20:1. (B) 51Cr-labeled EL4-
AAK cells that had been pulsed with the indicated concentration of ei-
ther murine (r) or human (j) tyrosinase peptides were incubated with
FMD 1 CTLs stimulated by and reactive with murine tyrosinase369–377 at
an E/T ratio of 20:1. (C) C1R-AAD target cells were infected for 8 h
with 10 PFU/cell of either rvv-mu tyr (j), rvv-hu tyr (m), or rvv-M1
(r). Cells were then labeled with 51Cr and incubated with a murine
tyrosinase369–377–reactive CTL line.1225 Colella et al.
tide in a cross-reactive manner (Fig. 2 A). To further
investigate the immunogenicity of murine tyrosinase in
AAD1tyrosinase1 mice, spleen cells from AAD1tyrosinase1
and AAD1 albino mice immunized with either rvv-mu tyr
or rvv-hu tyr were cultured with stimulators pulsed with
either the murine or human peptides and analyzed for their
ability to make IFN-g in response to either peptide (Fig.
6). As expected, AAD1 albino mice responded well to both
rvv-mu tyr and rvv-hu tyr. The T cells elicited were largely
cross-reactive, based on their activation and differentiation
in response to either peptide during 7 d of in vitro culture,
as well as their subsequent ability to be induced to produce
IFN-g in a 5-h incubation. In contrast, AAD1tyrosinase1
mice failed to respond to rvv-mu tyr based on the lack of
any detectable response in spleen cells cultured for 7 d with
either the murine or human peptides. Consistent with our
previous observations (Fig. 5, and reference 44), spleen
cells from AAD1tyrosinase1 mice immunized with rvv-hu
tyr and cultured in vitro for 7 d with the human peptide
led to their activation and differentiation as measured by
their ability to produce IFN-g when induced with the hu-
man peptide for 5 h. Significantly, many of these T cells
also recognized the murine tyrosinase-derived peptide as
judged by their ability to make IFN-g when induced with
the murine peptide for 5 h. However, in parallel cultures
of T cells from these same rvv-hu tyr–immunized
AAD1tyrosinase1  mice, this murine tyrosinase-derived
peptide did not cause activation and differentiation during a
7-d in vitro culture. These data establish that there are
residual murine tyrosinase-specific T cells in AAD1
tyrosinase1 mice but that their ability to respond to the
murine peptide is impaired.
Induction of Vitiligo following the Adoptive Transfer of
FMDGTMSQV-reactive T Cells into Normal Mice. The
preceding results indicated that the expression of tyrosinase
in AAD1 animals led to the development of partial toler-
ance towards the FMDGTMSQV peptide presented by
AAD. However, they did not clearly establish whether this
Ag was directly presented by melanocytes. Therefore, we
conducted adoptive transfer experiments to determine
whether FMDGTMSQV-specific CTLs could mediate
melanocyte destruction in vivo (vitiligo). An FMDGTM-
SQV-specific CTL line that was derived from AAD1 al-
bino mice (FMD 1) was transferred subcutaneously into ir-
Figure 3. Cytotoxic T cell responses to murine
tyrosinase369–377 in tyrosinase1 and tyrosinase2 AAD1
mice. Splenocytes from (A) AAD1c38R145L/c38R145L
mice, (B) AAD1c1/c38R145L mice, (C) AAD1c1 mice,
or (D) AAD2c38R145L/c38R145L mice that had been im-
munized with rvv-mu tyr were cultured for 6 d in the
presence of 1 mM FMDGTMSQV. CTL activity was
measured on 51Cr-labeled EL4-AAK (j, u) or EL4
(d,  s) cells that had been pulsed with 1 mM
FMDGTMSQV (filled symbols) or left unpulsed
(open symbols). Data are representative of six inde-
pendent experiments.
Figure 4. The T cell response
to murine tyrosinase369–377 in
tyrosinase2 mice is AAD re-
stricted. CTLs from AAD1 al-
bino mice that had been gener-
ated as in the legend to Fig. 3 A
were assayed for activity using
Con A blast targets from either
AAD1 albino mice (j,  u) or
AAD2 albino mice (d, s) that
had been either pulsed with
FMDGTMSQV (filled symbols)
or left unpulsed (open symbols).
Figure 5. Ex vivo T cell response to murine tyrosinase369–377 in
AAD1tyrosinase1 and AAD1 albino mice as measured by IFN-g produc-
tion. 7 d after intravenous immunization with 107 rvv-mu tyr or rvv-hu
tyr, CD81 cells were enriched from splenocytes, stimulated for 5 h with
synthetic FMDGTMSQV (murine peptide) or YMDGTMSQV (human
peptide), and assayed for the intracellular accumulation of IFN-g as de-
scribed in Materials and Methods.1226 Tolerance to Murine Homologue of Tyrosinase-derived Melanoma Antigen
radiated AAD1tyrosinase1 recipients together with IL-2. 4 wk
after subcutaneous transfer, mice exhibited significant vitiligo
as evidenced by depigmentation of the hair in the vicinity of
the injection site (Fig. 7 A, and Table II). At 4 wk after treat-
ment, vitiligo was not observed in mice that received IL-2
alone or were irradiated but did not receive either CTLs or
IL-2 (Table II). As expected, transfer of the same number of
CTLs specific for the HLA-A2–restricted influenza M158–66
epitope in combination with IL-2 failed to cause vitiligo.
These results indicate that normal melanocytes in AAD1
tyrosinase1 mice express the tyrosinase Ag in the context of
AAD and are targets for CTL-mediated destruction.
We also tested the ability of a tyrosinase-specific CTL
line derived from AAD1tyrosinase1 mice to mediate viti-
ligo. CJL CTL was induced by immunization with rvv hu
tyr, but showed equivalent recognition of both human and
murine peptides (Fig. 2 A). In addition, the doses of the
murine peptide required for half-maximal recognition are
comparable to those of intermediate avidity CTLs obtained
from albino AAD mice (compare Fig. 2, A and B; see also
Table III). Using the same number of transferred CTLs,
Figure 6. Characteristics of residual tyrosinase-spe-
cific response in AAD1tyrosinase1 mice. 3 wk after
immunization with either rvv-mu tyr or rvv-hu tyr,
splenocytes from AAD1tyrosinase1 mice or AAD1 al-
bino mice were cultured in vitro with an irradiated
feeder layer that had been pulsed with 1 mg/ml of ei-
ther synthetic FMDGTMSQV (murine) or YMDGT-
MSQV (human) peptides. 7 d later, cultures were har-
vested, stimulated for 5 h with C1R-AAD cells that
had been pulsed with synthetic FMDGTMSQV or
YMDGTMSQV, and assayed for the intracellular ac-
cumulation of IFN-g.
Figure 7. Induction of vitiligo after the adoptive transfer of tyrosinase-
specific T cells into AAD1tyrosinase1 mice. FMD 1, a CTL line derived
from AAD1 albino mice, was transferred subcutaneously into AAD1
tyrosinase1 mice (A). CJL, a CTL line derived from AAD1tyrosinase1
mice, was transferred subcutaneously into either AAD1tyrosinase1 (B) or
AAD2tyrosinase1 (C) mice. Photographs were taken 5 wk after transfer;
those shown are representative of multiple mice in each group (for n val-
ues, see Table II).
Table II. Induction of Vitiligo in AAD1Tyrosinase1 Mice by 
Adoptive Transfer of Tyrosinase-specific CTLs
CTLs Origin Specificity Host IL-2 Vitiligo n
FMD 1 Albino-AAD Antityrosinase AAD 1 111 6
None NA NA AAD 12 15
None NA NA AAD 226
M1 B6-AAD
Anti-
influenza M1 AAD 12 12
CJL B6-AAD Antityrosinase AAD 1 111 15
CJL B6-AAD Antityrosinase B6 122
CJL B6-AAD Antityrosinase AAD 216
All hosts were irradiated (700 rads) and received one of the regimens
described above (see Materials and Methods). Vitiligo intensity was
scored as the relative number of depigmented follicles within the 1-cm2
area of transfer. Mice were scored 4 wk after transfer as: 2, none; 1,
,30%; 111, .70%. B6, C57BL/6.1227 Colella et al.
vitiligo occurred in these mice with a comparable time
course and intensity (Fig. 7 B, and Table II). In contrast,
these CTLs did not mediate vitiligo in AAD2tyrosinase1
mice, and their induction of vitiligo in the absence of ex-
ogenous IL-2 was significantly diminished (Fig. 7 C, and
Table II). Interestingly, we have not observed vitiligo in
any animals immunized with recombinant vaccinia virus
expressing either human or murine tyrosinase (n . 20), nor
in mice immunized with either FMDGTMSQV or
YMDGTMSQV peptides pulsed onto dendritic cells (n 5
8) (data not shown). Collectively, these results demonstrate
that at least some of the residual tyrosinase-specific CTLs in
AAD1tyrosinase1 mice are capable of mediating vitiligo,
but only when appropriately activated.
Discussion
In this report, we have established and characterized a
murine model system to further our understanding of the
human CTL response to the HLA-A*0201–restricted Ag
derived from tyrosinase. Subsequent to the discovery that
Ags derived from MDPs, such as tyrosinase, constitute a
major target for melanoma-reactive CTLs, it was also es-
tablished that murine MDPs encode peptide Ags that are
presented in the context of murine class I molecules (45).
While these models offer the possibility to determine the
impact of these Ags on both antitumor immune responses
and self-tolerance, the advantage of the system described in
this report is that it permits the evaluation of an Ag that is
highly homologous in structure, behavior, and expression
to a human Ag that is currently in clinical trials for the
treatment of melanoma.
The homologous murine peptide derived from tyrosi-
nase differs from the human Ag by a single conservative
amino acid change at P1. As a consequence, the binding af-
finities of the two peptides for HLA-A*0201 are nearly
identical, and CTLs raised against one Ag frequently cross-
react on the other. Most important, murine tyrosinase is
endogenously processed, leading to the presentation of the
murine peptide in association with HLA-A*0201. These
similarities enabled us to use AAD1 albino mice to evaluate
whether the tyrosinase-derived Ag is expressed on melano-
cytes in vivo and how it affects the development of an
HLA-A*0201–restricted Ag-specific CTL response. This is
the first model system established for studying self-tolerance
to an Ag expressed on melanocytes. Using this unique
model, we determined that the murine homologue of tyros-
inase is naturally processed and presented in the context of
AAD in tyrosinase1 mice in vivo and that this presentation
has a tolerizing effect on the immune response.
The expression of tyrosinase protein and/or RNA is
confined to neural crest–derived melanocytes (14, 46, 47),
substantia nigra and forebrain (48), and chorioid and retinal
pigment epithelium (46, 49). Because tyrosinase expression
appears limited to a small number of tissues, self-tolerance
to the tyrosinase-derived Ag is likely to be mediated by a
peripheral rather than a central mechanism. However, one
study has demonstrated that tyrosinase transcripts can be
detected in a wide range of tissues after 60 cycles of PCR
amplification (50), suggesting that very low-level tyrosinase
expression is widespread. It was hypothesized that this
might be due to the presence of melanocytes in these tis-
sues, resulting from the arrested migration of neural crest
cells during development. This observation leaves open the
possibility that self-tolerance to tyrosinase might arise
through a central mechanism. Studies are currently under
way to evaluate the role of the thymus in the mechanism of
self-tolerance to tyrosinase and to determine whether toler-
ance to the tyrosinase-derived Ag can be mediated directly
by melanocytes or indirectly through cross-presentation by
bone marrow–derived cells (51–53).
Regardless of the exact mechanisms responsible, our data
show convincingly that self-tolerance is incomplete. Low
levels of cytotoxic and IFN-g1CD81 T cells specific for
FMDGTMSQV are demonstrable in AAD1tyrosinase1
mice after priming and in vitro restimulations, and these
T cells induce vitiligo upon adoptive transfer into AAD1
tyrosinase1 mice. In addition, peptide dose–response curves
show that the avidity of these CTLs is comparable to that
of high avidity CTLs generated in AAD1 albino mice un-
der similar priming conditions. Collectively, these results
demonstrate that at least some of the murine tyrosinase-
specific T cells in AAD1tyrosinase1 mice are of high avid-
ity. This appears to be at odds with previous observations
that peripheral expression of influenza HA under the con-
trol of the insulin promoter leads to a selective loss of high
avidity CTLs (54). However, it is clear that the site of pro-
tein expression, level of protein expression, and the accessi-
bility to the immune system contribute to the mechanism
of tolerance to self-Ags expressed in the periphery (55, 56).
In addition, it is also clear that the detection of murine ty-
rosinase-specific T cells in AAD1tyrosinase1 mice is not
straightforward. These cells do not appear to activate and/
or differentiate in response to murine tyrosinase in vivo or
in vitro. However, this failure can be circumvented by the
use of human tyrosinase, and subsequently, the ability of
these cells to recognize murine tyrosinase can be demon-
strated either by cytolysis or IFN-g secretion. These obser-
vations are reminiscent of the responses of T cells to altered
Table III. Avidity of CTL Lines for Murine Tyrosinase Peptide
CTL line SD50
mg/ml
CJL 7.25
FMD 10 30
FMD 1 10
FMD 0.1 8.75
FMD 0.01 2
CTL lines were generated as described (see Materials and Methods).
SD50 values are the average of three (FMD 10) or four (CJL, FMD 1,
FMD 0.1, and FMD 0.01) independent determinations.1228 Tolerance to Murine Homologue of Tyrosinase-derived Melanoma Antigen
peptide ligands that function as partial agonists (57–59). It is
frequently observed that partial agonists fail to induce pro-
liferation, although they do induce cytolysis and the secre-
tion of at least some cytokines (60, 61). Further work will
be required to fully understand the recognition of the mu-
rine tyrosinase peptide by these cells.
The results of this study are also particularly interesting
in light of recent work on tolerance to a keratinocyte-spe-
cific Ag (62). It was demonstrated that Ag-specific CTL
precursors that arise during the first 4–6 wk of life are ren-
dered tolerant due to circulation through the epidermis.
Although access to the epidermis ceases after this time, sub-
sequently arising T cells are tolerized by an undefined alter-
nate mechanism. The major sites of expression of tyrosi-
nase, as well as other MDP-derived Ags, are in the
melanocytes of the skin, or tissues sequestered behind the
blood–brain barrier. It will be of interest to determine if ac-
cess to the epidermis is necessary for tolerance to these Ags,
and whether the activation requirements of residual high
avidity FMDGTMSQV-specific CTLs in tyrosinase1 mice
are a reflection of this alternate tolerizing mechanism.
In this study, the development of vitiligo in tyrosinase1
mice after the transfer of FMDGTMSQV-reactive CTLs
indicates that this murine tyrosinase-derived peptide is ex-
pressed in the context of AAD on normal melanocytes.
This direct in vivo analysis complements and extends ear-
lier work in which the expression of the homologous hu-
man tyrosinase-derived peptide was demonstrated on me-
lanocytes cultured in the presence of growth factors and
phorbol esters (32; and our unpublished results). It has pre-
viously been demonstrated that vitiligo in mice can be in-
duced as a consequence of antibody responses to TRP-1
(63–65) or CD81 CTL responses against an unknown anti-
gen expressed on B16 melanoma (66). Interestingly, it has
been demonstrated that vitiligo in both models is associated
with tumor regression and protective antitumor immune
responses (57–59). Because of the similarities between hu-
man and mouse tyrosinase, the expression of the tyrosinase-
derived peptide in the context of the AAD molecule on
murine melanocytes in the present study strongly suggests
that the human tyrosinase peptide is also expressed in the
context of HLA-A*0201 on normal human melanocytes.
This leads us to suggest that immune responses to tyrosinase
may also lead to the hypopigmentation that is often ob-
served in association with clinical responses in melanoma
patients. In addition, it suggests that the use of this Ag in
immunotherapeutic treatment of melanoma may result in
vitiligo. Our results offer the possibility of developing a
model system in which vitiligo-inducing CTL responses
against a known human antigen can be studied for their
impact on tumor regression.
The observations made in the murine model system de-
scribed here allow us to make inferences about the impor-
tance of human tyrosinase as a tumor Ag. Our results sug-
gest that the expression of tyrosinase in human melanocytes
will lead to a diminished number of activatable CTLs that
recognize the peptide YMDGTMSQV in the context of
HLA-A*0201. Nonetheless, it remains important to define
the conditions for optimal activation and expansion of
these cells in vivo to engender an active therapeutic re-
sponse. The model system described here offers an impor-
tant and useful approach to this issue.
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